MUC1 and neoplasm: Importantly, the in vivo CTL assay revealed a significant antigen-specific cytotoxic T lymphocyte response in mice immunized with NLE-formulated MUC1 mRNA, confirming that the vaccine is capable of eliciting functional CD8+ T cell responses against tumor antigens [37].